Base Pair Biotechnologies specializes in the discovery and development of aptamers, which are short, single-stranded nucleic acids that can bind to specific targets with high affinity and specificity. Their services include custom aptamer discovery, bioinformatics for aptamer selection, and assay development. The company employs advanced techniques such as Multiplex SELEX, allowing for the simultaneous selection of aptamers for multiple targets, which enhances efficiency in identifying specific and pan-binders. Base Pair's approach is consultative, working closely with clients to tailor solutions that address unique project challenges, ensuring that each aptamer is optimized for its intended application.

Aptamers offer several advantages over traditional antibodies, including the ability to target smaller molecules, reduced immunogenicity, and enhanced stability. Base Pair Biotechnologies focuses on a wide range of applications for aptamers, including drug discovery, therapeutic development, and environmental testing. Their expertise extends to various fields such as immuno-oncology, neurological diseases, and food safety, where aptamers can be utilized for biomarker detection and diagnostics. The company emphasizes the importance of functional success in real-world applications, employing rigorous testing and optimization processes to ensure the effectiveness of their aptamer products.

United States

Base Pair Biotechnologies, Inc. offers rapid discovery of high quality aptamer (DNA- and RNA-based) affinity ligands.  Aptamers have been successfully employed in virtually every application where antibodies are typically used.  Aptamers have a number of potential advantages over antibodies, however, in a variety of applications.  

Base Pair Bio's aptamer discovery is powered by a patented, multiplexed approach to aptamer identification.  This and other chemical enhancements result in better DNA affinity ligands.

For more information, please visit www.basepairbio.com.

Base Pair Biotechnologies

Company Details